These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22316369)

  • 1. Benign and malignant apocrine lesions of the breast.
    Gerhard R; Costa JL; Schmitt F
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):215-21. PubMed ID: 22316369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on apocrine lesions of the breast.
    O'Malley FP; Bane A
    Histopathology; 2008 Jan; 52(1):3-10. PubMed ID: 18171412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and diagnostic features of apocrine breast lesions.
    Gromov P; Espinoza JA; Gromova I
    Expert Rev Mol Diagn; 2015; 15(8):1011-22. PubMed ID: 26111757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
    D'Arcy C; Quinn CM
    J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
    Celis JE; Gromova I; Gromov P; Moreira JM; Cabezón T; Friis E; Rank F
    FEBS Lett; 2006 May; 580(12):2935-44. PubMed ID: 16631754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
    Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
    Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases.
    Moriya T; Sakamoto K; Sasano H; Kawanaka M; Sonoo H; Manabe T; Ito J
    Mod Pathol; 2000 Jan; 13(1):13-8. PubMed ID: 10658905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenge of apocrine proliferations of the breast: a morphologic approach.
    Masood S; Rosa M
    Pathol Res Pract; 2009; 205(3):155-64. PubMed ID: 19147303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
    Shim HS; Jung WH; Kim H; Park K; Cho NH
    APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
    Tramm T; Kim JY; Tavassoli FA
    Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Apocrine lesions in breast pathology].
    Suciu V; Menet E; Guinebretière JM; Trassard M; Vielh P
    Ann Pathol; 2009 Nov; 29 Spec No 1():S112-3. PubMed ID: 19887237
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
    Jongen L; Paridaens R; Floris G; Wildiers H; Neven P
    Breast Cancer Res Treat; 2016 Feb; 155(3):603-7. PubMed ID: 26868122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encapsulated apocrine papillary carcinoma of the breast: case report with clinicopathologic and immunohistochemical study.
    Laforga JB; Gasent JM; Sánchez I
    Diagn Cytopathol; 2011 Apr; 39(4):288-93. PubMed ID: 20734358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enigmatic nature of apocrine breast lesions.
    Zagorianakou P; Zagorianakou N; Stefanou D; Makrydimas G; Agnantis NJ
    Virchows Arch; 2006 May; 448(5):525-31. PubMed ID: 16570182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apocrine carcinoma of the breast: a comprehensive review.
    Vranic S; Schmitt F; Sapino A; Costa JL; Reddy S; Castro M; Gatalica Z
    Histol Histopathol; 2013 Nov; 28(11):1393-409. PubMed ID: 23771415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apocrine adenoma of the breast.
    Cashell AW
    W V Med J; 2008; 104(2):16-9. PubMed ID: 18491794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fine-needle aspiration cytologic features of four special types of breast cancers: mucinous, medullary, apocrine, and papillary.
    Haji BE; Das DK; Al-Ayadhy B; Pathan SK; George SG; Mallik MK; Abdeen SM
    Diagn Cytopathol; 2007 Jul; 35(7):408-16. PubMed ID: 17580344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
    Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
    Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.